3 October 2024 F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic.
Swedish firm Enzymatica (STO: ENZY) will conduct a rights issue to raise approximately $12 million, with existing shareholders being given preferential rights. 18 July 2024
Privately-held German drugmaker Boehringer Ingelheim has inked a deal with GoodRx (Nasdaq: GDRX), in a bid to boost US penetration of its biosimilar to Humira (adalimumab). 18 July 2024
60% of listed Indian pharmaceutical companies have experienced an uptick in new business inquiries from US pharma companies due to the discussions around the US Biosecure Act. 18 July 2024
A new research paper concluding that the use of Inpefa (sotagliflozin) for the treatment of patients hospitalized for heart failure (HF) and suffering from co- morbid diabetes leads to significant positive impact on provider health system financial outcomes. 18 July 2024
Boehringer Ingelheim has entered partnership with AI company Brainomix for a collaborative program of activity to improve the care of patients with fibrosing lung disease in the USA. 18 July 2024
The show is over for Aslan Pharmaceuticals, the immunology-focused biopharmaceutical company, as its financial troubles have led it to file for voluntary liquidation. 18 July 2024
French pharma major Sanofi announced that full results from the XTEND-Kids Phase III study have been published in The New England Journal of Medicine (NEJM). 18 July 2024
Swiss pharma giant Novartis (NOVN: VX) has reported an impressive second quarter, with net sales increasing by 11% and core operating income rising by 19% to reach $5 billion. 18 July 2024
Russian drugmaker Promomed is aiming to accelerate expansion in both domestic and foreign markets in the coming years, reports The Pharma Letter’s local correspondent. 18 July 2024
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday announced it has approved two new medicines for use in Great Britain. 18 July 2024
Basel, Switzerland-based Roche has announced promising new, four-year data from the RHONE-X extension study, the largest long-term study on diabetic macular edema (DME). 18 July 2024
Trade association has called on the authorities of Russia to make adjustments for the methods of calculation of the initial maximum price of contracts (IMCP) for public procurements of drugs. 17 July 2024
The Phase III ARANOTE trial met its primary endpoint, significantly increasing radiological progression-free survival (rPFS) with darolutamide + androgen deprivation therapy (ADT) compared to placebo plus ADT, says Bayer. 17 July 2024
As the World Health Organization (WHO) calls for advancements to combat serious infections, one American firm is raising awareness about its work on nanoparticles. 17 July 2024
Relay Therapeutics in a Securities and Exchange Commission (SEC) filing that it has received notice of termination of the collaboration and license agreement with Genentech 17 July 2024
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Abivax ABVX) today announced the results of an interim efficacy and safety analysis of an open-label maintenance (OLM) study that enrolled patients with ulcerative colitis (UC). 3 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.